Lexaria Bioscience Corp.

KELOWNA, BC / ACCESS Newswire / September 17, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is providing the following update. Lexaria is in a strong cash position following both its recently announced Australian tax refund and recent institutional financing priced at US$12.92/share. The combined net … Continue reading Lexaria Updates Financial Position The post Lexaria Updates Financial Position appeared first on Lexaria Bioscience.

KELOWNA, BC / ACCESS Newswire / September 9, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, today closed its previously announced exercise of certain outstanding warrants to purchase an aggregate of 453,969 shares of the Company’s common stock originally issued by the Company on February 16, … Continue reading Lexaria Announces Closing of Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds The post Lexaria Announces Closing of Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds appeared first on Lexaria Bioscience.

KELOWNA, BC / ACCESS Newswire / September 8, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase an aggregate of 453,969 shares of the Company’s common stock originally issued by … Continue reading Lexaria Announces Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds The post Lexaria Announces Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds appeared first on Lexaria Bioscience.

KELOWNA, BC / ACCESS Newswire / September 4, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (“Lexaria” or the “Company”), a global innovator in oral drug delivery platforms, announces that it will participate in the 28th Annual H.C. Wainwright Global Investment Conference, taking place September 14th through September 16th, 2026 in New York City. Richard Christopher, CEO … Continue reading Lexaria to Present at the H.C. Wainwright 28th Annual Global Investment Conference The post Lexaria to Present at the H.C. Wainwright 28th Annual Global Investment Conference appeared first on Lexaria Bioscience.

Lexaria’s 2025 Australian human study results in a USD$2.6 million cash rebate KELOWNA, BC / ACCESS Newswire / September 1, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (“Lexaria” or the “Company”), a global innovator in oral drug delivery platforms, is pleased to announce that it has received a cash rebate of AUD$3,666,611.98 from the Australian Tax … Continue reading Lexaria Receives USD$2.6 Million Tax Rebate Payment The post Lexaria Receives USD$2.6 Million Tax Rebate Payment appeared first on Lexaria Bioscience.

Proprietary DehydraTECH 3.0 amycretin tablet formulation more than doubled absolute bioavailability compared to a leading industry study Proprietary DehydraTECH 3.0 retatrutide tablet formulation increased drug absorption by as much as an astonishing 4,552% compared to the DehydraTECH 2.0 retatrutide tablet evaluated Findings support Lexaria’s expanding strategic partnering outreach activities by evidencing DehydraTECH benefits for oral … Continue reading DehydraTECH™-enhanced Amycretin and Retatrutide Yield Significant Absorption Improvements in Lexaria’s 2026 Animal Study #2 The post DehydraTECH™-enhanced Amycretin and Retatrutide Yield Significant Absorption Improvements in Lexaria’s 2026 Animal Study #2 appeared first on Lexaria Bioscience.

KELOWNA, BC / ACCESS Newswire / August 13, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the “Company” or “Lexaria“), a global innovator in drug delivery platforms, announces that it has entered into a Material Transfer Agreement (“MTA“) with Pegbio Co., Ltd (“PegBio“) to investigate Lexaria’s DehydraTECH technology with a proprietary PegBio molecule under development for the … Continue reading Lexaria Enters a Material Transfer Agreement With PegBio The post Lexaria Enters a Material Transfer Agreement With PegBio appeared first on Lexaria Bioscience.

KELOWNA, BC / ACCESS Newswire / July 30, 2026 / Lexaria Bioscience Corp. (Nasdaq:LEXX) (the “Company” or “Lexaria“), a global innovator in drug delivery platforms, announces that it intends to effect a reverse stock split of its common stock effective as of 12:01 am EST on August 3, 2026 (the “Reverse Split“). The primary goal … Continue reading Lexaria Announces Effective Date for Reverse Stock Split The post Lexaria Announces Effective Date for Reverse Stock Split appeared first on Lexaria Bioscience.

KELOWNA, BC / ACCESS Newswire / July 6, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the “Company” or “Lexaria“), a global innovator in drug delivery platforms, is pleased to have experienced many positive meetings with potential pharmaceutical partners and collaborators at the 2026 BIO International Convention (“BIO”) in San Diego, CA. “Lexaria had a full schedule … Continue reading Lexaria Updates Business Development The post Lexaria Updates Business Development appeared first on Lexaria Bioscience.

KELOWNA, BC / ACCESS Newswire / June 25, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the “Company” or “Lexaria“), a global innovator in drug delivery platforms, announces that dosing began on schedule on June 14th with Human Pilot Study #7 (GLP-1-H26-7) that is evaluating two oral DehydraTECH-semaglutide (“DHT-sema”) compositions against Novo Nordisk’s® (“Novo”) commercially available Wegovy® … Continue reading Lexaria’s Human Study GLP-1-H26-7 Has Begun Dosing on Schedule The post Lexaria’s Human Study GLP-1-H26-7 Has Begun Dosing on Schedule appeared first on Lexaria Bioscience.